Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pegzilarginase in Subjects <24 Months Old With Arginase 1 Deficiency
NCT06582524Phase 3Completed
- Sponsor
- Immedica
- Start
- Aug 2024
- Primary completion
- Jun 2025
- Modality
- PEGylated Peptides, Replacement Enzymes
- Countries
- 3
01
Overview
Phase 3, open-label, single-arm trial of pegzilarginase in arginase 1 deficiency (ARG1-D), sponsored by Immedica. Primary endpoint: Change From Baseline in Plasma Arginine Concentrations at 12 weeks. Started Aug 2024; status: completed.
02
Drugs
pegzilarginase
03
Conditions
arginase 1 deficiency (ARG1-D)
Beyond the preview
Go deeper on NCT06582524.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06582524.